Novo Nordisk Initiates Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Jan 27, 2025 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, regulation, capital-return
TL;DR
Novo Nordisk is buying back its own stock, following EU rules.
AI Summary
Novo Nordisk A/S announced on January 27, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance with European regulations MAR and Commission Delegated Regulation (EU) 2016/1052.
Why It Matters
This indicates the company is returning capital to shareholders, potentially signaling confidence in its financial health and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine report on a share repurchase program, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- November 11, 2024 (date) — Initiation date of share repurchase program
- January 27, 2025 (date) — Date of announcement
- Regulation No 596/2014 (regulation) — European regulation governing the program
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — European regulation governing the program
FAQ
When did Novo Nordisk initiate its share repurchase program?
Novo Nordisk initiated its share repurchase program on November 11, 2024.
What is the announcement date of this share repurchase program update?
The announcement was made on January 27, 2025.
Which European regulations govern this share repurchase program?
The program is conducted in accordance with Article 5 of Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
What is the company's principal executive office address?
The principal executive offices are located at Novo Allé 1 DK-2880, Bagsvaerd, Denmark.
Is Novo Nordisk filing an annual report under Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under Form 20-F.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-27 09:01:03
Filing Documents
- f6k_012725.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-000429.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: January 27, 2025 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer